KRAS and cancer: The first study of clinical acquired resistance after treatment by KRAS G12C direct inhibition in cancer was described for adagrasib monotherapy in KRYSTAL-1 trail, with histologic and genomic analysis of samples (tissue or ctDNA) obtained at the time of disease progression and compared with available results of sequencing before adagrasib treatment for a small number of patients [47].